Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11834506B2 · kind B2 · utility
9Cited by
46References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 8, 2018 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | Oct 25, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Multi-specific binding proteins that bind a tumor associated antigen, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.